Key adverse events from the TRuE-V studies are highlighted.
In this segment of the discussion on vitiligo, Gary Owens, M.D., and David Rosmarin, M.D.,delve into the adverse events associated with the long-term use of the drug ruxolitinib. They emphasize the importance of considering both efficacy and safety in drug evaluation. Notably, they highlight that there have been no new side effects observed in the long-term extension of the study that were not previously seen in the initial phase. They discuss the similarities in infection results between patients initially using ruxolitinib cream and those switched from a vehicle to the medication. The experts express their views that the reported adverse events are likely random occurrences, not directly related to the treatment. They specifically mention the common occurrences of application site acne and pruritus. Overall, the discussion underscores the safety profile of the drug, emphasizing its topical nature and limited impact on the body surface area.
Video synopsis is AI-generated and reviewed by Managed Health Care Executive editorial staff.